Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $59.1 million.

  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) rose 142.38% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 142.38%. This contributed to the annual value of $58.1 million for FY2024, which is 133.86% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Shares Outstanding (Weighted Average) of $59.1 million as of Q3 2025, which was up 142.38% from $59.0 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $59.1 million in Q3 2025 and a low of $55.1 million during Q1 2021
  • Over the past 5 years, Vanda Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $57.4 million (recorded in 2023), while the average stood at $57.2 million.
  • In the last 5 years, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) soared by 248.94% in 2021 and then skyrocketed by 129.16% in 2024.
  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $55.5 million in 2021, then grew by 1.64% to $56.5 million in 2022, then rose by 1.63% to $57.4 million in 2023, then increased by 1.34% to $58.1 million in 2024, then rose by 1.62% to $59.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $59.1 million in Q3 2025, compared to $59.0 million in Q2 2025 and $58.5 million in Q1 2025.